Reporting of adverse event data in hematopoietic stem cell transplantation clinical trials involving investigational new drugs or devices: A report from the William Guy Forbeck Foundation 2001 Focus Meeting on clinical stem cell transplantation

被引:5
作者
Martin, PJ
Antin, JH
Weisdorf, DJ
Paton, V
Horowitz, MM
机构
[1] Fred Hutchinson Canc Res Ctr D2 100, Seattle, WA 98109 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Univ Minnesota, Minneapolis, MN USA
[4] Cerus Corp, Concord, CA USA
[5] Int Bone Marrow Transplant Registry, Milwaukee, WI USA
关键词
hematopoietic stem cell transplantation; adverse events; monitoring;
D O I
10.1016/S1083-8791(02)50027-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The William Guy Forbeck Foundation was established in 1984 in memory of William Guy Forbeck, an 11-year-old boy who died of neuroblastoma. The objectives of the Forbeck Foundation are to promote advances and shorten the research timetable in the field of oncology, particularly pediatric oncology. The Foundation's centerpiece activity is an annual scientific forum held at Hilton Head Island, South Carolina, where 12 to 15 leading scientists from a variety of disciplines associated with a specific topic are invited to participate in a private "think tank" environment, where they can freely exchange ideas in the hope of building on each other's knowledge and experience. Additionally, the Foundation sponsors grants for Focus Meetings, which are designed to give other researchers an opportunity to conduct their own meetings along the lines of the Foundation's annual forum. The idea for this Focus Meeting was born during the 2000 Annual Forbeck Forum in South Carolina, which considered the current status of allogeneic hematopoietic stem cell transplantation (HSCT). Participants considered various obstacles to conducting clinical trials in this area and decided to bring together experts from academia, industry, and government to discuss ways in which these obstacles might be overcome. Topics included efficient clinical trial designs, issues of monitoring and reporting adverse events, and appropriate definitions and grading systems for transplantation-specific outcomes. This article summarizes the issue of adverse event reporting in HSCT.
引用
收藏
页码:295 / 302
页数:8
相关论文
共 8 条
[1]  
[Anonymous], 1994, CLIN SAF DAT MAN DEF
[2]  
[Anonymous], 1995, STRUCT CONT CLIN STU
[3]  
*FOOD DRUG ADM, 2001, CANC DRUG BIOL PROD
[4]  
International Conference on Harmonization, 1996, GUID GOOD CLIN PRACT
[5]  
*NAT CANC I CANC T, 1999, COMM TOX CRIT VERS 2
[6]  
*NAT CANC I CANC T, 2001, NCI GUID EXP ADV EV
[7]  
National Cancer Institute Cancer Therapy Evaluation Program, 1999, COMM TOX CRIT MAN
[8]  
NIKAS J, 1997, DRUG INF J, V31, P63